In-depth genomic characterization of pre-treatment biopsies and later timepoints in early stage HER2+ breast cancer together with predictive modelling has the potential to identify biomarkers of neoadjuvant therapy tumour response. This evidence concerns the gene ERBB2 and breast carcinoma.